Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma

44Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Toll-like receptor 9 (TLR9) is a cellular DNA-receptor whose activation with cognate ligands triggers an immune reaction, with increased production of inflammatory cytokines. The aim of this study was to examine the expression of TLR9 in renal cell carcinoma (RCC), which is generally renowned of its immunogenic nature. We also evaluated the prognostic value of TLR9 in RCC. Methods. TLR9 expression in RCC was characterized with immunohistochemistry in a retrospective study population of 152 RCC patients who underwent renal surgery. The TLR9 staining intensity was compared with clinical parameters. Results: Of the studied tumours, 112 (81%) exhibited cytoplasmic TLR9 immunostaining. No association was detected between cytoplasmic TLR9 immunoexpression intensity and stage, nuclear grade, histological subtype or tumour necrosis. Cytoplasmic TLR9 immunoexpression was, however, a marker of favourable RCC specific survival both in univariate analysis and in multivariate regression model. Conclusions: We conclude that TLR9 expression is an independent prognostic marker of RCC and the absence of TLR9 expression is related to poorer prognosis in RCC. © 2011 Ronkainen et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Ronkainen, H., Hirvikoski, P., Kauppila, S., Vuopala, K. S., Paavonen, T. K., Selander, K. S., & Vaarala, M. H. (2011). Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 30(1). https://doi.org/10.1186/1756-9966-30-84

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free